In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Grand Eagle Retail, Bensenville, IL, USA
Hardcover. Zustand: new. Hardcover. In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Bestandsnummer des Verkäufers 9783725867707
Anbieter: PBShop.store US, Wood Dale, IL, USA
HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers L2-9783725867707
Anzahl: Mehr als 20 verfügbar
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers L2-9783725867707
Anzahl: Mehr als 20 verfügbar
Anbieter: California Books, Miami, FL, USA
Zustand: New. Bestandsnummer des Verkäufers I-9783725867707
Anzahl: Mehr als 20 verfügbar
Anbieter: Rarewaves.com USA, London, LONDO, Vereinigtes Königreich
Hardback. Zustand: New. Bestandsnummer des Verkäufers LU-9783725867707
Anzahl: Mehr als 20 verfügbar
Anbieter: CitiRetail, Stevenage, Vereinigtes Königreich
Hardcover. Zustand: new. Hardcover. In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Bestandsnummer des Verkäufers 9783725867707
Anzahl: 1 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing. Bestandsnummer des Verkäufers 9783725867707
Anzahl: 2 verfügbar
Anbieter: Rarewaves.com UK, London, Vereinigtes Königreich
Hardback. Zustand: New. Bestandsnummer des Verkäufers LU-9783725867707
Anzahl: Mehr als 20 verfügbar
Anbieter: preigu, Osnabrück, Deutschland
Buch. Zustand: Neu. Emerging Antibody Engineering Strategies and Applications for Immunotherapy of Cancer | Buch | Englisch | 2026 | MDPI AG | EAN 9783725867707 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. Bestandsnummer des Verkäufers 134934030
Anzahl: 5 verfügbar